The Regulatory Affairs track provided an insight into the latest trends and cutting edge technology in drug development from both the pharmaceutical/biotech industry and regulatory authority perspectives. As anticipated the presentations from the major regulatory agencies (FDA, EMEA, HC etc) and some of the GCC countries Êcovered the regulatory aspects of drug development and drug life cycle, generic drugs and pharmacovigilance and risk management
strategies. Delegates were given the opportunity to gain insight from presenters with substantial collective, regulatory and pharmaceutical industry experience and expertise.
